Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
10.8M
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
188K
-
Shares change
-
+23.4K
-
Total reported value, excl. options
-
$467K
-
Value change
-
+$60K
-
Number of buys
-
6
-
Number of sells
-
-4
-
Price
-
$2.48
Significant Holders of Phio Pharmaceuticals Corp. - Common Stock, par value $0.0001 per share (PHIO) as of Q3 2025
14 filings reported holding PHIO - Phio Pharmaceuticals Corp. - Common Stock, par value $0.0001 per share as of Q3 2025.
Phio Pharmaceuticals Corp. - Common Stock, par value $0.0001 per share (PHIO) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 188K shares
of 10.8M outstanding shares and own 1.75% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (87.6K shares), GEODE CAPITAL MANAGEMENT, LLC (57.9K shares), Cetera Investment Advisers (33.5K shares), MORGAN STANLEY (6K shares), BANK OF AMERICA CORP /DE/ (1.4K shares), SBI Securities Co., Ltd. (1.1K shares), BNP PARIBAS FINANCIAL MARKETS (413 shares), Tower Research Capital LLC (TRC) (406 shares), ASSETMARK, INC (110 shares), and UBS Group AG (13 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.